

PATIENT NAME: DEEPIKA BALHALA REF. DOCTOR:

ACCESSION NO: 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO

AGE/SEX :31 Years :20/03/2023 08:50:05 DRAWN RECEIVED: 20/03/2023 08:52:03 REPORTED :21/03/2023 11:50:30

Biological Reference Interval Test Report Status Results Units <u>Final</u>

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

XRAY-CHEST

BOTH THE LUNG FIELDS ARE CLEAR

BOTH THE COSTOPHRENIC AND CARIOPHRENIC ANGELS ARE CLEAR

BOTH THE HILA ARE NORMAL

CARDIAC AND AORTIC SHADOWS APPEAR NORMAL **»**» BOTH THE DOMES OF THE DIAPHRAM ARE NORMAL >> >>

VISUALIZED BONY THORAX IS NORMAL **»**»

NO ABNORMALITY DETECTED **IMPRESSION**

TMT OR ECHO

TMT OR ECHO 2D ECHO TEST IS DONE RESULT : NEGATIVE

ECG

WITHIN NORMAL LIMITS **ECG**

MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT RELEVANT PAST HISTORY NOT SIGNIFICANT **NOT SIGNIFICANT** RELEVANT PERSONAL HISTORY NOT SIGNIFICANT RELEVANT FAMILY HISTORY OCCUPATIONAL HISTORY NOT SIGNIFICANT HISTORY OF MEDICATIONS NOT SIGNIFICANT

ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.51 mts WEIGHT IN KGS. 69 Kgs **BMI** 30 BMI & Weight Status as follows/sqmts

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight

30.0 and Above: Obese

GENERAL EXAMINATION

NORMAL MENTAL / EMOTIONAL STATE **NORMAL** PHYSICAL ATTITUDE **HEALTHY** GENERAL APPEARANCE / NUTRITIONAL

STATUS

BUILT / SKELETAL FRAMEWORK AVERAGE

R. Swarupa.

Dr.R.Swarupa **Consultant Pathologist**





Page 1 Of 20

PERFORMED AT:

SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA

Tel: 9111591115, Fax CIN - U74899PB1995PLC045956





ACCESSION NO: 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO : AGE/SEX :31 Years Female DRAWN :20/03/2023 08:50:05 RECEIVED :20/03/2023 08:52:03 REPORTED :21/03/2023 11:50:30

Test Report Status <u>Final</u> Results Biological Reference Interval Units

FACIAL APPEARANCE NORMAL
SKIN NORMAL
UPPER LIMB NORMAL
LOWER LIMB NORMAL
NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND NOT ENLARGED

CAROTID PULSATION NORMAL BREAST (FOR FEMALES) NORMAL TEMPERATURE NORMAL

PULSE 76/REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT

RESPIRATORY RATE NORMAL

CARDIOVASCULAR SYSTEM

BP 140/100 MM HG mm/Hg

(SITTING) NORMAL

ABSENT

PERICARDIUM NORMAL
APEX BEAT NORMAL
HEART SOUNDS NORMAL
MURMURS ABSENT

RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST

MOVEMENTS OF CHEST

BREATH SOUNDS INTENSITY

NORMAL

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS ABSENT

PER ABDOMEN

APPEARANCE NORMAL
VENOUS PROMINENCE ABSENT
LIVER NOT PALPABLE
SPLEEN NOT PALPABLE

CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS NORMAL

R. Swarupa.

HERNIA

Dr.R.Swarupa Consultant Pathologist Page 2 Of 20





View Details

View Repor

PERFORMED AT:

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003







ACCESSION NO : 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO : AGE/SEX :31 Years Female
DRAWN :20/03/2023 08:50:05
RECEIVED :20/03/2023 08:52:03
REPORTED :21/03/2023 11:50:30

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CRANIAL NERVES NORMAL
CEREBELLAR FUNCTIONS NORMAL
SENSORY SYSTEM NORMAL
MOTOR SYSTEM NORMAL
REFLEXES NORMAL

MUSCULOSKELETAL SYSTEM

SPINE NORMAL JOINTS NORMAL

BASIC EYE EXAMINATION

CONJUNCTIVA NORMAL
EYELIDS NORMAL
EYE MOVEMENTS NORMAL
CORNEA NORMAL
DISTANT VISION RIGHT EYE WITH GLASSES 6/12
DISTANT VISION LEFT EYE WITH GLASSES 6/12

NEAR VISION RIGHT EYE WITH GLASSES WITHIN NORMAL LIMIT NEAR VISION LEFT EYE WITH GLASSES WITHIN NORMAL LIMIT

COLOUR VISION NORMAL

BASIC ENT EXAMINATION

EXTERNAL EAR CANAL NORMAL TYMPANIC MEMBRANE NORMAL

NOSE NO ABNORMALITY DETECTED

SINUSES NORMAL

THROAT NO ABNORMALITY DETECTED

TONSILS NOT ENLARGED

BASIC DENTAL EXAMINATION

TEETH NORMAL GUMS HEALTHY

SUMMARY

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT

RELEVANT LAB INVESTIGATIONS wbc-10.10,hba1c-5.8,chol-239,sgot-52,sgpt-73,ggt-84,ldh-344.

R. Swarupa.

Dr.R.Swarupa Consultant Pathologist



Page 3 Of 20

View Details

View Report

PERFORMED AT:

SRL Ltd
LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD
SECUNDERABAD, 500003





PATIENT NAME : DEEPIKA BALHALA

ACCESSION NO : 0042WC003821
PATIENT ID : DEEPF10039242A
CLIENT PATIENT ID:
ABHA NO : ACCESSION NO : 20/03/2023 08:50:05
REPORTED : 21/03/2023 11:50:30

Test Report Status <u>Final</u> Results Biological Reference Interval Units

RELEVANT NON PATHOLOGY DIAGNOSTICS REMARKS / RECOMMENDATIONS

obese.

ADVICE TO FOLLOWUP WITH PHYSICIAN IF SYMPTOMATIC FOR MILD

LEUCOCTOSIS.

ADVICE TO FOLLOW UP WITH PHYSICIAN FOR RAISED HBA1C. ADVICE TO FOLLOW UP WITH PHYSICIAN FOR HIGH CHOLESTEROL

LEVELS.

ADVICE TO FOLLOW UP WITH PHYSICIAN FOR RAISED LIVER ENZYMES. NEEDS SIGNIFICANTS WEIGHT REDUCTION, PHYSICAL EXCERCISES ARE SUGGEST. AVOID OILY AND JUNK FOODS. HAVE DIETICIAN

OPINION FOR WEIGHT REDUCTION.

FITNESS STATUS

FITNESS STATUS FIT (WITH MEDICAL ADVICE) (AS PER REQUESTED PANEL OF TESTS)

R. Swarupa.

Dr.R.Swarupa Consultant Pathologist





Page 4 Of 20

View Details





SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME: DEEPIKA BALHALA REF. DOCTOR: ACCESSION NO: 0042WC003821 AGE/SEX :31 Years Female :20/03/2023 08:50:05 PATIENT ID : DEEPF10039242A DRAWN CLIENT PATIENT ID: RECEIVED: 20/03/2023 08:52:03 REPORTED :21/03/2023 11:50:30 ABHA NO

Test Report Status Biological Reference Interval Final Results Units

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE **ULTRASOUND ABDOMEN ULTRASOUND ABDOMEN**

NO ABNORMALITIES DETECTED

Interpretation(s)

HISTORY-THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

FITNESS STATUS-Conclusion on an individual's Fitness, which is commented upon mainly for Pre employment cases, is based on multi factorial findings and does not depend

on any one single parameter. The final Fitness assigned to a candidate will depend on the Physician's findings and overall judgement on a case to case basis, details of the candidate's past and personal history; as well as the comprehensiveness of the diagnostic panel which has been requested for . These are then further correlated with details of the job under consideration to eventually fit the right man to the right job.

- Basis the above, SRL classifies a candidate's Fitness Status into one of the following categories:
 Fit (As per requested panel of tests) SRL Limited gives the individual a clean chit to join the organization, on the basis of the General Physical Examination and the specific test panel requested for.
- Fit (with medical advice) (As per requested panel of tests) This indicates that although the candidate can be declared as FIT to join the job, minimal problems have been detected during the Pre- employment examination. Examples of conditions which could fall in this category could be cases of mild reversible medical abnormalities such as height weight disproportions, borderline raised Blood Pressure readings, mildly raised Blood sugar and Blood Lipid levels, Hematuria, etc. Most of these relate to sedentary lifestyles and come under the broad category of life style disorders. The idea is to caution an individual to bring about certain lifestyle changes as well as seek a Physician'''s consultation and counseling in order to bring back to normal the mildly deranged parameters. For all purposes the individual is FIT to join the job.
- Fitness on Hold (Temporary Unfit) (As per requested panel of tests) Candidate's reports are kept on hold when either the diagnostic tests or the physical findings reveal the presence of a medical condition which warrants further tests, counseling and/or specialist opinion, on the basis of which a candidate can either be placed into Fit, Fit (With Medical Advice), or Unfit category. Conditions which may fall into this category could be high blood pressure, abnormal ECG, heart murmurs, abnormal vision, grossly elevated blood sugars, etc.
- Unfit (As per requested panel of tests) An unfit report by SRL Limited clearly indicates that the individual is not suitable for the respective job profile e.g. total color blindness in color related jobs

R. Swarupa.

Dr.R.Swarupa **Consultant Pathologist** Page 5 Of 20





PERFORMED AT:

LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME: DEEPIKA BALHALA REF. DOCTOR: ACCESSION NO: 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO

AGE/SEX :31 Years Female :20/03/2023 08:50:05 DRAWN RECEIVED: 20/03/2023 08:52:03 REPORTED :21/03/2023 11:50:30

Test Report Status <u>Final</u> Results Biological Reference Interval Units

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECKUP BI	LOW 40FEMALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD: CYANMETHEMOGLOBIN METHOD	15.0	12.0 - 15.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	5.74 High	3.8 - 4.8	mil/μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	10.10 High	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: ELECTRICAL IMPEDANCE	219	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	46.2 High	36 - 46	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	81.0 Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	26.2 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	32.5	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	12.5	11.6 - 14.0	%
MENTZER INDEX	14.1		
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	10.0	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD: ACV TECHNOLOGY	65	40 - 80	%
LYMPHOCYTES METHOD: ACV TECHNOLOGY	28	20 - 40	%
MONOCYTES METHOD: ACV TECHNOLOGY	4	2 - 10	%
EOSINOPHILS METHOD: ACV TECHNOLOGY	2	1 - 6	%

Dr. Ravi Teja J **Consultant Pathologist**



Page 6 Of 20

PERFORMED AT:

SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME: DEEPIKA BALHALA REF. DOCTOR:

ACCESSION NO: 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO

:20/03/2023 08:50:05 DRAWN RECEIVED: 20/03/2023 08:52:03 REPORTED :21/03/2023 11:50:30

:31 Years

AGE/SEX

Test Report Status <u>Final</u>	Results	Biological Reference Int	erval Units
BASOPHILS	1	0 - 2	%
METHOD : ACV TECHNOLOGY			
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	6.57	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER	2.83	1.0 - 3.0	thou/µL
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER	0.40	0.2 - 1.0	thou/µL
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER	0.20	0.02 - 0.50	thou/μL
ABSOLUTE BASOPHIL COUNT METHOD: CALCULATED PARAMETER	0.10	0.02 - 0.10	thou/µL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD: CALCULATED	2.3		
MORPHOLOGY			
RBC METHOD: MICROSCOPIC EXAMINATION	NORMOCYTIC NORMOCHROMIC WITH FEW MICROCYTES.		
WBC	WITHIN NORMAL	LIMITS.	
METHOD: MICROSCOPIC EXAMINATION			
PLATELETS	ADEQUATE ON SMEAR.		

METHOD: MICROSCOPIC EXAMINATION

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

was Differentiable Contribute Contribute and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Ravi Teja J **Consultant Pathologist**





Page 7 Of 20

PERFORMED AT:

LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





REF. DOCTOR: PATIENT NAME: DEEPIKA BALHALA

> ACCESSION NO: 0042WC003821 AGE/SEX

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO

:31 Years :20/03/2023 08:50:05 DRAWN RECEIVED: 20/03/2023 08:52:03

REPORTED :21/03/2023 11:50:30

Test Report Status Biological Reference Interval <u>Final</u> Results Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

0 - 20mm at 1 hr E.S.R

METHOD: WESTERGREN METHOD

Interpretation(s)
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Ravi Teja J Consultant Pathologist





Page 8 Of 20

PERFORMED AT:

LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





ACCESSION NO: 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO

AGE/SEX :31 Years Female :20/03/2023 08:50:05 DRAWN RECEIVED: 20/03/2023 08:52:03

REPORTED :21/03/2023 11:50:30

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: TUBE AGGLUTINATION

RH TYPE **POSITIVE**

METHOD: TUBE AGGLUTINATION

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Ravi Teja J **Consultant Pathologist**



Page 9 Of 20

PERFORMED AT:

SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME: DEEPIKA BALHALA REF. DOCTOR:

ACCESSION NO: 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO

:20/03/2023 08:50:05 RECEIVED: 20/03/2023 08:52:03 REPORTED :21/03/2023 11:50:30

:31 Years

AGE/SEX

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 95 74 - 99 mg/dL

METHOD: SPECTROPHOTOMETRY HEXOKINASE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

HBA1C 5.8 High Non-diabetic: < 5.7 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: ION-EXCHANGE HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 119.8 High < 116.0 mg/dL

METHOD: ION-EXCHANGE HPLC

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 106 70 - 139 mg/dL

METHOD: SPECTROPHOTOMETRY HEXOKINASE

LIPID PROFILE, SERUM

239 High mg/dL < 200 Desirable CHOLESTEROL, TOTAL

200 - 239 Borderline High

>/= 240 High

METHOD: SPECTROPHOTOMETRY, CHOLESTEROL OXIDASE ESTERASE PEROXIDASE

TRIGLYCERIDES 67 < 150 Normal mg/dL

150 - 199 Borderline High

200 - 499 High >/=500 Very High

METHOD: SPECTROPHOTOMETRY, LIPASE

mg/dL HDL CHOLESTEROL 54 < 40 Low

>/=60 High

METHOD: SPECTROPHOTOMETRY, POLYANIONIC DETERGENT/CHOD

Dr. Ravi Teja J **Consultant Pathologist**





Page 10 Of 20



SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME : DEEPIKA BALHALA

REF. DOCTOR :

ACCESSION NO : 0042WC003821
PATIENT ID : DEEPF10039242A
CLIENT PATIENT ID:
ABHA NO :

REF. DOCTOR :

AGE/SEX :31 Years Female
DRAWN :20/03/2023 08:50:05
RECEIVED :20/03/2023 08:52:03
REPORTED :21/03/2023 11:50:30

Test Report Status <u>Final</u>	Results	Biological Reference Interval Units
CHOLESTEROL LDL	172 High	< 100 Optimal mg/dL 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High
NON HDL CHOLESTEROL	185 High	Desirable: Less than 130 mg/dL Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220
VERY LOW DENSITY LIPOPROTEIN CHOL/HDL RATIO	13.4 4.4	<pre><!--= 30.0 mg/dL 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk --> 11.0 High Risk</pre>
LDL/HDL RATIO	3.2 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk
Interpretation(s)		
LIVER FUNCTION PROFILE, SERUM		
BILIRUBIN, TOTAL METHOD: SPECTROPHOTOMETRY, JENDRASSIK & GROFF	0.81	0.2 - 1.0 mg/dL
BILIRUBIN, DIRECT METHOD: SPECTROPHOTOMETRY, JENDRASSIK & GROFF	0.06	0.0 - 0.2 mg/dL
BILIRUBIN, INDIRECT METHOD: SPECTROPHOTOMETRY, CALCULATED	0.75	0.1 - 1.0 mg/dL
TOTAL PROTEIN METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET	9.0 High	6.4 - 8.2 g/dL
ALBUMIN METHOD: SPECTROPHOTOMETRY, BCP - DYE BINDING	4.3	3.4 - 5.0 g/dL

Lulu

Dr. Ravi Teja J Consultant Pathologist Page 11 Of 20





View Details

View Repor

PERFORMED AT:

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME: DEEPIKA BALHALA REF. DOCTOR:

ACCESSION NO: 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID:

DRAWN :20/03/2023 08:50:05
RECEIVED :20/03/2023 08:52:03
REPORTED :21/03/2023 11:50:30

:31 Years

AGE/SEX

Test Report Status <u>Final</u>	Results	Biological Reference I	nterval Units
GLOBULIN	4.7 High	2.0 - 4.1	g/dL
METHOD: SPECTROPHOTOMETRY, CALCULATED			
ALBUMIN/GLOBULIN RATIO	0.9 Low	1.0 - 2.1	RATIO
METHOD: SPECTROPHOTOMETRY, CALCULATED			
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: SPECTROPHOTOMETRY, UV WITH PYRIDOXAL -5-PHO	52 High DSPHATE	15 - 37	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	73 High	< 34.0	U/L
METHOD : SPECTROPHOTOMETRY, UV WITH PYRIDOXAL -5-PHO	OSPHATE		
ALKALINE PHOSPHATASE	113	30 - 120	U/L
METHOD: SPECTROPHOTOMETRY, P-NPP (AMP BUFFER)			
GAMMA GLUTAMYL TRANSFERASE (GGT)	84 High	5 - 55	U/L
METHOD: SPECTROPHOTOMETRY, G-GLUTAMYL-CARBOXY-NITR	RONILIDE		
LACTATE DEHYDROGENASE	344 High	100 - 190	U/L
METHOD: SPECTROPHOTOMETRY, MODIFIED ENZYMATIC LACTA	ATE - PYRUVATE		
BLOOD UREA NITROGEN (BUN), SERUM			
BLOOD UREA NITROGEN	10	6 - 20	mg/dL
METHOD: SPECTROPHOTOMETRY, UREASE UV			
CREATININE, SERUM			
CREATININE	0.58 Low	0.60 - 1.10	mg/dL
METHOD: SPECTROPHOTOMETRY, ALKALINE PICRATE KINETIC	JAFFE'S		
BUN/CREAT RATIO			
BUN/CREAT RATIO	17.24 High	5.00 - 15.00	
METHOD: SPECTROPHOTOMETRY, CALCULATED			
URIC ACID, SERUM			
URIC ACID	4.8	2.6 - 6.0	mg/dL
METHOD: SPECTROPHOTOMETRY, URICASE			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	9.0 High	6.4 - 8.2	g/dL
METHOD: SPECTROPHOTOMETRY, MODIFIED BIURET			
ALBUMIN, SERUM			
ALBUMIN	4.3	3.4 - 5.0	g/dL
METHOD: SPECTROPHOTOMETRY, BCP - DYE BINDING			
GLOBULIN			
GLOBULIN	4.7 High	2.0 - 4.1	g/dL
METHOD: SPECTROPHOTOMETRY, CALCULATED			

Lulu

Dr. Ravi Teja J Consultant Pathologist



Page 12 Of 20

View Details

View Repor

PERFORMED AT:

SRL Ltd

LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME: DEEPIKA BALHALA REF. DOCTOR: ACCESSION NO: 0042WC003821 AGE/SEX :31 Years Female :20/03/2023 08:50:05 PATIENT ID : DEEPF10039242A DRAWN CLIENT PATIENT ID: RECEIVED: 20/03/2023 08:52:03 REPORTED :21/03/2023 11:50:30 ABHA NO

Test Report Status	<u>Final</u>	Results	Biological Reference Interva	l Units
ELECTROLYTES (NA/	/K/CL), SERUM			
SODIUM, SERUM METHOD: INTEGRATED MUL	LTISENSOR TECHNOLOGY-INDIRECT	141	136 - 145	mmol/L
POTASSIUM, SERUM METHOD : INTEGRATED MUL	1 LTISENSOR TECHNOLOGY-INDIRECT	4.99	3.50 - 5.10	mmol/L
CHLORIDE, SERUM METHOD: INTEGRATED MUL	LTISENSOR TECHNOLOGY-INDIRECT	99	98 - 107	mmol/L

Interpretation(s)

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give



Dr. Ravi Teja J Consultant Pathologist





Page 13 Of 20

View Report

PERFORMED AT:

LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME: DEEPIKA BALHALA REF. DOCTOR: ACCESSION NO : 0042WC003821 AGE/SEX :31 Years Female :20/03/2023 08:50:05 PATIENT ID : DEEPF10039242A DRAWN CLIENT PATIENT ID: RECEIVED: 20/03/2023 08:52:03 REPORTED :21/03/2023 11:50:30 ABHA NO

Test Report Status Results **Biological Reference Interval Final** Units

yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction,

Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget"""'s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson"""'s disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom''''''s disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing

enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, mainutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,
Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.
CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract

- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum.. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom''''''''''''' disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage),Burns,Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Ravi Teja J **Consultant Pathologist** Page 14 Of 20





View Report

PERFORMED AT:

LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





ACCESSION NO: 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO

AGE/SEX :31 Years Female :20/03/2023 08:50:05 RECEIVED: 20/03/2023 08:52:03

REPORTED :21/03/2023 11:50:30

Biological Reference Interval Test Report Status Results Units <u>Final</u>

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

PHYSICAL EXAMINATION, URINE

PALE YELLOW **COLOR**

METHOD: MANUAL

SLIGHTLY HAZY APPEARANCE

METHOD: MANUAL

CHEMICAL EXAMINATION, URINE

PH 6.0 4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY

SPECIFIC GRAVITY 1.025 1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY

PROTEIN NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY

NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY **KETONES**

NOT DETECTED NOT DETECTED METHOD: REFLECTANCE SPECTROPHOTOMETRY

BLOOD

NOT DETECTED NOT DETECTED METHOD: REFLECTANCE SPECTROPHOTOMETRY

NOT DETECTED NOT DETECTED BII IRUBIN

METHOD: REFLECTANCE SPECTROPHOTOMETRY

NORMAL NORMAL UROBILINOGEN

METHOD: REFLECTANCE SPECTROPHOTOMETRY

NOT DETECTED NOT DETECTED NITRITE

METHOD: REFLECTANCE SPECTROPHOTOMETRY NOT DETECTED NOT DETECTED LEUKOCYTE ESTERASE

MICROSCOPIC EXAMINATION, URINE

/HPF **NOT DETECTED NOT DETECTED** RED BLOOD CELLS

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 3-5 0-5 /HPF METHOD: MICROSCOPIC EXAMINATION

0-5 /HPF

EPITHELIAL CELLS 2-3 METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED **CASTS**

Dr. Ravi Teja J **Consultant Pathologist** Page 15 Of 20





PERFORMED AT:

SRL Ltd LEGEND CRYSTAL, SHOP NO-6, GROUND & 1ST FLOOR, PLOT NO-1-7-79/A B:, PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA

Tel: 9111591115, Fax CIN - U74899PB1995PLC045956





ACCESSION NO : **0042WC003821**PATIENT ID : DEEPF10039242A

| DEEPF100392

CLIENT PATIENT ID:

AGE/SEX :31 Years Female
DRAWN :20/03/2023 08:50:05
RECEIVED :20/03/2023 08:52:03

REPORTED :21/03/2023 11:50:30

Test Report Status <u>Final</u> Results Biological Reference Interval Units

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

YEAST NOT DETECTED NOT DETECTED

Comments

NOTE: URINE MICROSCOPIC EXAMINATION IS CARRIED OUT ON CENTRIFUGED URINE SEDIMENT.

Interpretation(s)

Lulu

Dr. Ravi Teja J Consultant Pathologist



Page 16 Of 20

View Details

View Report

PERFORMED AT:

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





ACCESSION NO: 0042WC003821

PATIENT ID : DEEPF10039242A

CLIENT PATIENT ID: ABHA NO : AGE/SEX :31 Years Female DRAWN :20/03/2023 08:50:05 RECEIVED :20/03/2023 08:52:03

REPORTED :21/03/2023 11:50:30

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

MICROSCOPIC EXAMINATION, STOOL

REMARK

Interpretation(s)

SAMPLE NOT RECEIVED

M. Ja

Dr M. Prasanthi Consultant Microbiologist





Page 17 Of 20

View Details

View Report



SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME : DEEPIKA BALHALA

REF. DOCTOR :

ACCESSION NO : 0042WC003821
PATIENT ID : DEEPF10039242A
CLIENT PATIENT ID:
ABHA NO :

REF. DOCTOR :

AGE/SEX : 31 Years Female
DRAWN : 20/03/2023 08:50:05
RECEIVED : 20/03/2023 08:52:03
REPORTED : 21/03/2023 11:50:30

Test Report Status <u>Final</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP BELOW 40FEMALE

THYROID PANEL, SERUM

ng/dL T3 110.80 Non-Pregnant Women 80.0 - 200.0 Pregnant Women 1st Trimester: 105.0 - 230.0 2nd Trimester: 129.0 - 262.0 3rd Trimester: 135.0 - 262.0 METHOD: ECLIA 10.32 T4 Non-Pregnant Women μg/dL 5.10 - 14.10 Pregnant Women 1st Trimester: 7.33 - 14.80 2nd Trimester: 7.93 - 16.10 3rd Trimester: 6.95 - 15.70 METHOD: ECLIA μIU/mL TSH (ULTRASENSITIVE) 1.500 Non Pregnant Women 0.27 - 4.20Pregnant Women 1st Trimester: 0.33 - 4.59 2nd Trimester: 0.35 - 4.10 3rd Trimester: 0.21 - 3.15

METHOD : ECLIA

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. owidctlparowidctlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No. TSH Total T4 FT4 Total T3 Possible Conditions

Lulm

Dr. Ravi Teja J Consultant Pathologist Page 18 Of 20





View Details

View Report

PERFORMED AT:

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





PATIENT NAME : DEEPIKA BALHALA

ACCESSION NO : 0042WC003821
PATIENT ID : DEEPF10039242A
CLIENT PATIENT ID:
ABHA NO : ACCESSION NO : 20/03/2023 08:50:05
REPORTED : 21/03/2023 11:50:30

Test Report Status <u>Final</u> Results Biological Reference Interval Units

1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

Lulm

Dr. Ravi Teja J Consultant Pathologist





Page 19 Of 20

View Details

View Report

PERFORMED AT:

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA





 REF. DOCTOR :

 ACCESSION NO : 0042WC003821
 AGE/SEX : 31 Years Female

 PATIENT ID : DEEPF10039242A
 DRAWN : 20/03/2023 08:50:05

 CLIENT PATIENT ID: ABHA NO :
 RECEIVED : 20/03/2023 11:50:30

Test Report Status <u>Final</u> Results Biological Reference Interval Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Lulu

Dr. Ravi Teja J Consultant Pathologist Page 20 Of 20





View Details



PERFORMED AT:

SRL Ltd LEGEND CRYSTAL,SHOP NO-6,GROUND & 1ST FLOOR,PLOT NO-1-7-79/A B:,PRENDERGHAST ROAD SECUNDERABAD, 500003 TELANGANA, INDIA

